Physician profile
Stacey K Wright
NPI 1497716476
$5,641.13
in general payments reported to CMS, 2019-2025
21 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,148 · 2022: $895 · 2023: $1,770 · 2024: $639 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.51 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,276.56 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $760.36 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $705.48 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $453.64 | 2023-2025 | Ingrezza |
| Abbvie INC. | $447.51 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $370.29 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $319.63 | 2024-2025 | Cobenfy |
| Abiomed | $231.46 | 2022-2023 | Impella |
| Vanda Pharmaceuticals INC. | $158.23 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.39 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $145.29 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $143.49 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $112.76 | 2023 | Quviviq |
| Eisai INC. | $104.92 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $87.34 | 2021-2024 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $84.02 | 2021-2023 | Rexulti |
| Indivior INC. | $32.78 | 2022-2024 | Perseris |
| Merz North America, INC. | $19.00 | 2025 | |
| Merck Sharp & Dohme LLC | $18.07 | 2023 | Belsomra |
| Tris Pharma INC | $15.69 | 2023 | Dyanavel Xr |
| Corium, LLC | $7.22 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.